Compare NEOS S&P 500 High Income ETF (SPYI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NEOS S&P 500 High Income ETF vs TG Therapeutics Inc — how do they compare? NEOS S&P 500 High Income ETF trades at $53.5, while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). Which is the better fit depends on your goals.
| SPYI | TGTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $54.42 | $59.06 |
52-Week Low | $47.98 | $26.94 |
Market Cap | — | $8.36B |
Enterprise Value | — | $8.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPYI trades at $53.65, down 0.39% on the day, with a neutral technical signal. Recent dividend distributions of $0.53-$0.54 highlight its income focus, though news articles caution about tax implications and return of capital. The ETF's covered-call strategy aims for high yield amid low S&P 500 dividend payouts.
Outlook remains mixed; high monthly income appeals, but structural risks and tax complexity warrant caution. Competition from JEPI and capital erosion concerns present headwinds, while demand for yield in retirement portfolios supports relevance.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
